Investor Presentation
13
Investor presentation First six months of 2022
Following an interim analysis, the SELECT cardiovascular
outcomes trial continues in accordance with the trial protocol
SELECT trial with 17,500 people with obesity
Semaglutide 2.4 mg
R
1:1
Placebo
Event driven
5 weeks
follow-up
Objective
Demonstrate that semaglutide 2.4 mg lowers the incidence of MACE vs
placebo
Primary endpoint
Time from randomisation to first occurrence of MACE¹
Secondary endpoints
CV death, all-cause death, 5-point MACE composite, composite HF,
composite nephropathy, glucose metabolism, other metabolic
parameters
Estimated completion
The trial is expected to complete in the middle of 2023
1 MACE includes non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death.
MACE: Major adverse cardiovascular events; HF: Heart failure; CV: Cardiovascular
Novo NordiskⓇView entire presentation